We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Clinical evaluation demonstrates the safety and efficacy of eliglustat in Gaucher disease type 1, supporting its authorization as a first-line oral therapy.
Yale Univ, Sch Med, New Haven, CT USA
No takes yet. Share an insight, caveat, or question.
Mistry et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: